Although RICs provide a powerful tool to detect biochemical RNA binding in cells, only functional follow-up experiments can establish the biological relevance of newly detected RBPs. Candidate RBPs that will be selected for further characterization as drug targets should have a meaningful impact on key biological processes. In this WP2, we will disrupt RBP-RNA interactions in disease relevant cellular and in vivo models and examine how this affects pathophysiological processes. On the other hand, once potential drug targets are identified (WP4), their effectiveness in disease models has also to be demonstrated.
